Futuras estrategias terapéuticas en el tratamiento del cáncer de mama metastásico RE+/HER2-negativo: inhibidores CDK4/6 - page 19

B CDK1
A CDK1
A CDK2
E CDK2
Extent of Rb
phosphorylatio
n
dephosphorylation
D CDK4/6
Target of CDK4/6
inhibitors
hyperphosphorylati
on
Inactivates Rb
and allows
progression
p16
INK4a
Preclinical predicator of sensitivity
- High Cyclin D1
- High Rb
- Low p16
Paloma 1:
-
Cyclin D1 amplification or loss of
p16 unable to select group who
benefits
Finn, et al. Breast Cancer Res. 2009. Finn, et al. Lancet Oncol. 2015
Biomarker analysis
1...,9,10,11,12,13,14,15,16,17,18 20,21,22,23,24,25,26,27,28,29,...40
Powered by FlippingBook